Doxorubicin

Research use only, not for human use.

Doxorubicin is an Anthracycline Topoisomerase Inhibitor.

Doxorubicin is an Anthracycline Topoisomerase Inhibitor. The mechanism of action of doxorubicin is as a Topoisomerase Inhibitor. The chemical classification of doxorubicin is Anthracyclines.(In Vitro):Combination of Doxorubicin (Hydroxydaunorubicin) and Simvastatin in the highest tested concentrations (2 μM and 10 μM, respec-tively) kills 97% of the Hela cells.(In Vivo):Mice bearing PC3 xenografts are injected with 2, 4 or 8 mg/kg Doxorubicin (Hydroxydaunorubicin) and tumor volume is measured over time. A dose of 2 mg/kg does not affect tumor growth while higher dosages delay tumor growth initially (p<0.05 at days 18 and 22), 4 mg/kg or 8 mg/kg Doxorubicin significantly reduces levels of c-FLIP in PC3 xenografts. A single intraperitoneal injection 10 mg/kg (Doxorubicin 1) is administered in rats, 10 daily intraperitoneal injections of 1 mg/kg (Doxorubicin 2), or in 5 weekly intraperitoneal injections of 2 mg/kg (Doxorubicin 3). An 80% mortality rate is observed at day 28 in Doxorubicin 1, whereas Doxorubicin 2 and Doxorubicin 3 reached 80% mortality at days 107 and 98, respectively. Fractional shortening decreased by 30% at week 2 in Doxorubicin DOX1, 55% at week 13 in Doxorubicin 2, and 42% at week 13 in Doxorubicin 3.

——

Animal Model:Athymic male nude mice model of xenografts of PC3 prostate carcinoma cellsDosage:2 mg/kg, 4 mg/kg, 8 mg/kg Administration:ntraperitoneal injection (i.p.); Single dose .After injected PC3 cells (4 × 106) subcutaneously into the flank of mice. Result:A dose of 2 mg/ kg did not affect tumor growth while higher dosages (4 mg/kg, 8 mg/kg) delayed tumor growth initially. Animal Model:Male Sprague-Dawley rats model Dosage:10 mg/kg (schedule 1), 1 mg/kg (schedule 2), 2 mg/kg (schedule 3) Administration:Intraperitoneal injection (i.p.) ; Single dose (schedule 1).Intraperitoneal injection (i.p.); Once daily for 10 days (schedule 2).Intraperitoneal injection (i.p.); Once per week, for 5 weeks(schedule 3).Result:In schedule 1, caused 30% of the rats to die at the end of week 2 and 80% by day 28.In schedule 2 , caused 55% of the rats to die at the end of week 13 and 80% by day 107.In schedule 3, caused 42% of the rats to die at the end of week 13 and 80% by day 98.Animal Model: Male Sprague-Dawley rats Dosage:1%, 2%, 4%, 5%, 6%, 10%, 20%Administration:Intrastriatal injection; Single dose Result:In doses of 4, 5, 6, 10 or 20% caused obvious loss of ipsilateral SNc and VTA neuronsz and doses of 1 or 2% failed to produce obvious neuron loss.

——

Cell Cycle/DNA Damage

Topoisomerase

Topo II

Cancer

——

23214-92-8

543.52

C27H29NO11

>98% (HPLC)

DMSO: 10 mM

C[C@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2C[C@@](CC3=C(C4=C(C(=C23)O)C(=O)C5=C(C4=O)C=CC=C5OC)O)(C(=O)CO)O)N)O

——

(-20℃)

With Ice Pack

≥ 2 years